Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

A giant letter "L" was installed in the Lindsay Heights neighborhood on Tuesday, Nov. 12. It's one of six WaterMarkers in the city of Milwaukee. WaterMarkers show an illuminated blue letter, chosen b ...

BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

Cannabis Bioscience International Holdings (OTC Pink: CBIH) trading on the OTC Markets under the ticker symbol CBIH has ...

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes. Modifi Biosciences, a spin out of Yale University founded in 2021, ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company ...